Get the Stockscreener App
2.87
1.06%
0.03
After Hours:
2.87
Synaptogenix Inc Stock (SNPX) Latest News
Mustang Bio (NASDAQ:MBIO) Stock Quotes, Forecast and News Summary - Benzinga
ZyVersa Therapeutics (NASDAQ:ZVSA) Stock Quotes, Forecast and News Summary - Benzinga
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 1.18% - MSN
Finance Watch: As Cash Dwindles, Biotechs Cut Costs, Sell Assets, Merge, Assess Options - News & Insights
Synaptogenix Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength - Marketscreener.com
Synaptogenix (SNPX) Extends CEO’s Employment and Forms Special Committee to Explore Strategic Opportunities - Defense World
Synaptogenix forms committee to explore strategic opportunities - Investing.com
Synaptogenix forms committee to explore strategic opportunities By Investing.com - Investing.com South Africa
Synaptogenix Restructures Leadership Amid Strategic Refocus - TipRanks
Synaptogenix Forms Special Committee to Explore Strategic Options with $19.6M Cash Runway - StockTitan
Synaptogenix shareholders approve key proposals at annual meeting - Investing.com India
Synaptogenix shareholders approve key proposals at annual meeting By Investing.com - Investing.com Canada
Synaptogenix stock hits 52-week low at $2.71 amid market challenges - Investing.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q1 2024 - MSN
Comparing Synaptogenix (NASDAQ:SNPX) & Clever Leaves (NASDAQ:CLVR) - Defense World
Synaptogenix appoints new auditor as Morison Cogen exits - Investing.com
Synaptogenix appoints new auditor as Morison Cogen exits By Investing.com - Investing.com UK
Synaptogenix, Inc. announced that it expects to receive $3.207 million in funding - Marketscreener.com
Synaptogenix announces new preferred stock series - Investing.com
Synaptogenix Announces $5.0 Million Financing - citybiz
Synaptogenix stock hits 52-week low at $3.17 amid market challenges - Investing.com India
Synaptogenix secures $5 million in preferred stock financing - Investing.com India
Synaptogenix (NASDAQ:SNPX) Trading 2.6% Higher - Defense World
Synaptogenix extends preferred shares maturity date - Investing.com
Synaptogenix Inc (SNPX) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Pre-market Movers: BNRG, NCNA, PALT, ESTC, LUNR… - RTTNews
SNPX (Synaptogenix) Earnings per Share (Diluted) : $-37.19 (TTM As of Mar. 2024) - GuruFocus.com
SNPX Stock Earnings: Synaptogenix Reported Results for Q2 2024 - InvestorPlace
Synaptogenix’s PUFA analogues for spinal cord injury - BioWorld Online
Polyrizon (NASDAQ:PLRZ) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix cleared to launch Phase 1 trial of bryostatin-1 in MS - Multiple Sclerosis News Today
FDA grants IND authorisation for Synaptogenix’s multiple sclerosis trial - Clinical Trials Arena
Synaptogenix increases psilocybin stake with PsygaBio - Green Market Report
Synaptogenix announces reverse stock split to regain Nasdaq compliance By Investing.com - Investing.com South Africa
Why NVIDIA Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Markets Insider
CERo Therapeutics Hldgs (NASDAQ:CERO) Stock Quotes, Forecast and News Summary - Benzinga
Why AMD Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session - Markets Insider
Synaptogenix President Daniel L. Alkon, M.D. Honored for Scientific Presentation at USC-Sponsored Forum on Age-Related Diseases and Neurodegenerative Disorders - PR Newswire
Synaptogenix Acquires Significant Stake in Cannasoul Analtyics Ltd. Co-founded by The TechnionIsrael Institute of Technology - PR Newswire
Synaptogenix, Inc. acquired 25% minority stake in Cannasoul Analytics Ltd. for $4 million. - Marketscreener.com
'Extremely important outcome for Alzheimer's patients' following Synaptogenix trial - OutSourcing-Pharma.com
Advanced Alzheimer's: Bryostatin-1 may be safe, effective - Medical News Today
Bryostatin found to slow cognitive decline in advanced Alzheimer's... - Alzheimer's News Today
Niemann-Pick Disease Type C Market to Proliferate by 2032, Predicts DelveInsight | Key Companies in the MarketAzafaros A.G., Cyclo Therapeutics, Inc., ZevraDenmark, Genzyme, IntraBio Inc, Mandos Health - PR Newswire
Best Penny Stocks To Buy Now? 10 Under $1 To Watch - Penny Stocks
Best Penny Stocks To Buy Now? 3 Under $1 To Watch - Penny Stocks
Phase 1 trial of bryostatin-1 in MS expected by year's end |... - Multiple Sclerosis News Today
Biodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News Summary - Benzinga
Synaptogenix reports data from Phase II Alzheimer’s trial - Clinical Trials Arena
Synaptogenix's Alzheimer's prospect flops in NIH-sponsored study, sinking stock - Fierce Biotech
Theriva Biologics (AMEX:TOVX) Stock Quotes, Forecast and News Summary - Benzinga
Roche's drug failure extends long list of Alzheimer's trial setbacks - Reuters.com
PharmaCyte Biotech Reaches Cooperation Agreement with Iroquois Capital - Business Wire
1st Alzheimer's Patient Given Bryostatin in Dose-finding Trial |... - Alzheimer's News Today
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):